Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.55 |
| ▸ | HPN | P05981 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elsibucol SCHEMBL6002307 | 0.90 | VCAM1 (0.73) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL6000617 | 0.88 | VCAM1 (0.73) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14037559 | 0.85 | VCAM1 (0.70) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL13609380 | 0.85 | VCAM1 (0.63) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042598 | 0.83 | ALOX15 (0.62) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042599 | 0.82 | ALOX15 (0.60) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14586319 | 0.82 | VCAM1 (0.67) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14586314 | 0.82 | VCAM1 (0.53) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL5575964 | 0.82 | ALOX15 (0.64) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12012989 | 0.82 | VCAM1 (0.83) | VCAM1ALOX15HPNMAPTSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622604-B2 | via grignard intermediate such as benzylmagnesium chloride and esterification with succinic anhydride; inflammatory and cardiovascular diseases; optimizes the amount of monoester in the final product mixture and minimizes the amount of reagents; e.g. synthesis of succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | CRABTREE ACQUISITION CO, LLC | 2008-01-10 | — | — | US | disclosed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | NR3C2, MGLL, GCG | VCAM1 4649/4885ALOX15 1829/4885HPN 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.